Chester County News and Community Website
WARRINGTON, PA — Windtree Therapeutics, Inc. (NasdaqCM: WINT) announced that the U.S. Patent and Trademark Office has issued a new patent covering its lead investigational therapy, istaroxime, for intravenous treatment …
Windtree Therapeutics Secures U.S. Patent for Istaroxime Heart Failure Treatment Read More WARRINGTON, PA — Windtree Therapeutics, Inc. (NasdaqCM: WINT) has announced its plan to release interim data from the SEISMiC SCAI Stage C Phase 2 study (SEISMiC C Study) by July …
Windtree Therapeutics Targets July for Interim Data from Key Cardiogenic Shock Study Read More WARRINGTON, PA — Windtree Therapeutics, Inc. (NasdaqCM: WINT) has announced that the United States Patent and Trademark Office (USPTO) has issued a Notice of Allowance for U.S. patent application number …
Windtree Therapeutics Secures Patent for Istaroxime IV Formulation in Acute Heart Failure Read More
NEW HOPE, PA — Orchestra BioMed Holdings, Inc. (Nasdaq: OBIO) revealed promising new findings on its atrioventricular interval modulation (AVIM) therapy during a late-breaking presentation at the Technology and Heart Failure …
Orchestra BioMed Unveils Groundbreaking Data on AVIM Therapy’s Potential to Prevent Heart Failure Read More WARRINGTON, PA — Windtree Therapeutics, Inc. (NasdaqCM: WINT) has announced the issuance of a new patent for istaroxime in Hong Kong, titled “Istaroxime-containing intravenous formulation for the treatment of heart …
Windtree Therapeutics Secures Hong Kong Patent for Istaroxime in Heart Failure Treatment Read More WARRINGTON, PA — Windtree Therapeutics, Inc. (NasdaqCM: WINT) has announced a significant advancement in its cardiovascular portfolio with the issuance of a new patent for its drug istaroxime in Japan. The …
Windtree Therapeutics Secures Patent for Heart Failure Treatment in Japan Read More WARRINGTON, PA — Windtree Therapeutics, Inc. (NasdaqCM: WINT) has announced encouraging topline results from its Phase 2b SEISMiC Extension Study investigating istaroxime in patients experiencing early cardiogenic shock due to heart …
Windtree Therapeutics Announces Positive Results in Heart Failure Study Read More WARRINGTON, PA — Windtree Therapeutics, Inc. (NasdaqCM: WINT) has reported promising outcomes from its Phase 2b SEISMiC Extension Study, showcasing the potential of istaroxime in managing early cardiogenic shock caused by …
Windtree Therapeutics Announces Promising Results for Heart Failure Drug Read More WARRINGTON, PA — Windtree Therapeutics, Inc. (NasdaqCM: WINT), a biotech firm based in Bucks County, has shared significant updates on its novel heart failure therapy, istaroxime. This therapy aims to …
Windtree Therapeutics Advances Heart Failure Treatment in New Clinical Trials Read More
WASHINGTON, D.C. — The U.S. Food and Drug Administration (FDA) recently published a critical piece by Commissioner Robert M. Califf, M.D., titled “From Awareness to Action: Tackling the Rising Burden …
FDA Commissioner Highlights Rising Burden of Chronic Diseases Read More